Trial Profile
An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2018
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms FREEDOM-1 HBL
- Sponsors Intarcia Therapeutics
- 04 Jan 2018 Results assessing efficacy and tolerability of a continuous delivery subcutaneous formulation of exenatide in patients with type 2 diabetes mellitus that is inadequately controlled with diet and exercise alone or in combination with oral antihyperglycaemics with high baseline HbA1c, were published in the Diabetes Care.
- 19 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 16 Sep 2016 Results of procedure experience from this and other three trials of FREEDOM Phase 3 program (n=5200) presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.